Status:
ACTIVE_NOT_RECRUITING
Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy
Lead Sponsor:
Centre Francois Baclesse
Collaborating Sponsors:
ARCAGY/ GINECO GROUP
Conditions:
Germ Cell Tumor
Sex Cord Stromal Tumor
Eligibility:
FEMALE
18+ years
Phase:
NA
Brief Summary
While they are documented in patients in remission of testicular cancer, the sequelae of chemotherapy and the impact of the disease and its treatments on the living conditions and QoL of women in remi...
Eligibility Criteria
Inclusion
- Age\> 18 years;
- Patient with an ovarian malignant germ cell tumor (TGMO) or a stroma tumor and / or sex cords (TSCS) treated optimally;
- Patient who has had surgery and chemotherapy (interest group) or only a surgery (control group);
- Patient in remission more than 2 years after the end of the initial treatment;
- Relapse authorized if remission more than 2 years after the end of the treatment;
- Patient with no other cancers (with the exception of basal cell skin carcinomas, in situ cancers of the breast and cervix);
- Patient having signed his consent to participate
Exclusion
- Pregnant or breastfeeding woman;
- Psychiatric pathology that may disrupt the course of the study or prevent the interpretation of results;
- Person deprived of liberty;
- Major subject to a legal protection measure or unable to express his consent.
Key Trial Info
Start Date :
May 7 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
268 Patients enrolled
Trial Details
Trial ID
NCT03418844
Start Date
May 7 2018
End Date
December 1 2025
Last Update
September 22 2025
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
HEGP
Paris, Paris, France
2
Centre Paul Papin
Angers, France
3
CHU Besançon Jean MINJOZ
Besançon, France
4
Institut Bergonié
Bordeaux, France